Janus Henderson Group PLC Acquires 115,389 Shares of SurModics, Inc. (SRDX)

Janus Henderson Group PLC Acquires 115,389 Shares of SurModics, Inc. (SRDX)

Janus Henderson Group PLC lifted its holdings in SurModics, Inc. (NASDAQ:SRDX) by 54.8% during the first quarter, according to the company in its most recent filing with the SEC. The fund owned 325,885 shares of the company’s stock after buying an additional 115,389 shares during the quarter. Janus Henderson Group PLC’s holdings in SurModics were worth $14,169,000 as of its most recent filing with the SEC.

Several other institutional investors have also bought and sold shares of the company. BlackRock Inc. lifted its position in shares of SurModics by 1.7% in the 4th quarter. BlackRock Inc. now owns 2,108,214 shares of the company’s stock worth $99,634,000 after buying an additional 35,443 shares during the last quarter. Vanguard Group Inc lifted its position in shares of SurModics by 7.1% in the 3rd quarter. Vanguard Group Inc now owns 808,645 shares of the company’s stock worth $60,366,000 after buying an additional 53,835 shares during the last quarter. Vanguard Group Inc. lifted its position in shares of SurModics by 7.1% in the 3rd quarter. Vanguard Group Inc. now owns 808,645 shares of the company’s stock worth $60,366,000 after buying an additional 53,835 shares during the last quarter. Trigran Investments Inc. lifted its position in shares of SurModics by 9.9% in the 4th quarter. Trigran Investments Inc. now owns 795,202 shares of the company’s stock worth $37,581,000 after buying an additional 71,478 shares during the last quarter. Finally, Bank of New York Mellon Corp lifted its position in shares of SurModics by 5.7% in the 3rd quarter. Bank of New York Mellon Corp now owns 164,535 shares of the company’s stock worth $12,284,000 after buying an additional 8,912 shares during the last quarter. Institutional investors own 86.58% of the company’s stock.

A number of research firms have recently issued reports on SRDX. Barrington Research set a $64.00 price target on shares of SurModics and gave the stock a “buy” rating in a research report on Thursday, May 2nd. Zacks Investment Research downgraded shares of SurModics from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, April 2nd. BidaskClub upgraded shares of SurModics from a “strong sell” rating to a “sell” rating in a research report on Wednesday, April 24th. Needham & Company LLC reaffirmed a “buy” rating and issued a $74.00 price objective (up previously from $69.00) on shares of SurModics in a report on Thursday, February 21st. Finally, ValuEngine cut shares of SurModics from a “strong-buy” rating to a “buy” rating in a report on Monday, March 25th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and four have given a buy rating to the stock. SurModics has a consensus rating of “Buy” and a consensus target price of $68.00.

Shares of SRDX opened at $40.60 on Thursday. The company has a market capitalization of $539.67 million, a PE ratio of 82.86, a price-to-earnings-growth ratio of 13.34 and a beta of 1.24. SurModics, Inc. has a 12-month low of $39.06 and a 12-month high of $82.35.

SurModics (NASDAQ:SRDX) last announced its quarterly earnings data on Wednesday, May 1st. The company reported $0.07 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.02) by $0.09. The company had revenue of $22.68 million for the quarter, compared to analysts’ expectations of $21.01 million. SurModics had a negative net margin of 2.07% and a positive return on equity of 6.35%. Research analysts expect that SurModics, Inc. will post 0.3 earnings per share for the current fiscal year.

In other news, VP Joseph J. Stich sold 2,000 shares of SurModics stock in a transaction that occurred on Friday, February 15th. The shares were sold at an average price of $55.25, for a total value of $110,500.00. Following the transaction, the vice president now owns 55,894 shares of the company’s stock, valued at approximately $3,088,143.50. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Gary R. Maharaj sold 5,000 shares of SurModics stock in a transaction that occurred on Monday, April 1st. The stock was sold at an average price of $42.90, for a total transaction of $214,500.00. The disclosure for this sale can be found here. Insiders sold a total of 16,569 shares of company stock worth $775,863 in the last ninety days. Corporate insiders own 6.30% of the company’s stock.

About SurModics

Surmodics, Inc, together with its subsidiaries, provides medical devices and in vitro diagnostic technologies to the healthcare industry in the United States and internationally. The company operates through two segments, Medical Device and In Vitro Diagnostics. The Medical Device segment designs, develops, and manufactures interventional medical devices primarily for the peripheral vascular market; and offers surface modification coating technologies to enhance access, deliverability, and predictable deployment of medical devices, as well as drug delivery coating technologies to provide site-specific drug delivery from the surface of a medical device for the coronary, peripheral, neuro-vascular, urology, and other markets.

Further Reading: Is it Safe to Invest in Commodities?

Want to see what other hedge funds are holding SRDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for SurModics, Inc. (NASDAQ:SRDX).

Related posts

Leave a Comment